Base de dados : LILACS
Pesquisa : D06.347.295.500 [Categoria DeCS]
Referências encontradas : 2 [refinar]
Mostrando: 1 .. 2   no formato [Detalhado]

página 1 de 1

  1 / 2 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1001152
Autor: Morales-Conde, Macarena; López-Ibáñez, Natividad; Calvete-Candenas, Julio; Mendonça, Francisco Manuel Ildefonso.
Título: Fulvestrant-induced toxic epidermal necrolysis
Fonte: An. bras. dermatol;94(2):218-220, Mar.-Apr. 2019. tab, graf.
Idioma: en.
Resumo: Abstract Toxic epidermal necrolysis is a condition with massive keratinocyte apoptosis, and it is associated with high mortality rates. Fulvestrant, an estrogen receptor antagonist, is indicated in the treatment of estrogen receptor-positive metastatic breast cancer in postmenopausal women. To our knowledge, this is the first described case of toxic epidermal necrolysis due to fulvestrant. A 56-year-old woman received 500 mg of intramuscular fulvestrant monthly for metastatic ductal carcinoma of the breast. Five days after the first dose, the patient presented with a maculopapular rash that evolved to blisters, and a detachment of the epidermis in over 30% of the total body surface area. Histological analysis was compatible with toxic epidermal necrolysis. Fulvestrant was discontinued, topical management and supportive care were initiated.
Descritores: Pele/patologia
Síndrome de Stevens-Johnson/etiologia
Antagonistas do Receptor de Estrogênio/efeitos adversos
/efeitos adversos
AMERICAN HEART ASSOCIATIONACCOUNTING/efeitos adversos
-Neoplasias Encefálicas/tratamento farmacológico
Neoplasias Encefálicas/secundário
Síndrome de Stevens-Johnson/patologia
Antagonistas do Receptor de Estrogênio/uso terapêutico
/uso terapêutico
AMERICAN HEART ASSOCIATIONACCOUNTING/uso terapêutico
Necrose
Limites: Humanos
Feminino
Pessoa de Meia-Idade
Tipo de Publ: Relatos de Casos
Responsável: BR1.1 - BIREME


  2 / 2 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-762903
Autor: Xu, B.L.; Zhao, Q.Z.; Gao, X.Y.; Hou, G.J..
Título: Effect of estradiol and bisphenol A on human hepatoblastoma cell viability and telomerase activity
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;48(11):1004-1009, Nov. 2015. tab, graf.
Idioma: en.
Resumo: Sex hormones from environmental and physiological sources might play a major role in the pathogenesis of hepatoblastoma in children. This study investigated the effects of estradiol and bisphenol A on the proliferation and telomerase activity of human hepatoblastoma HepG2 cells. The cells were divided into 6 treatment groups: control, bisphenol A, estradiol, anti-estrogen ICI 182,780 (hereinafter ICI), bisphenol A+ICI, and estradiol+ICI. Cell proliferation was measured based on average absorbance using the Cell Counting-8 assay. The cell cycle distribution and apoptotic index were determined by flow cytometry. Telomerase activity was detected by polymerase chain reaction and a telomeric repeat amplification protocol assay. A higher cell density was observed in bisphenol A (P<0.01) and estradiol (P<0.05) groups compared with the control group. Cell numbers in S and G2/M phases after treatment for 48 h were higher (P<0.05), while the apoptotic index was lower (P<0.05) and telomerase activities at 48 and 72 h (P<0.05) were higher in these groups than in the control group. The cell density was also higher in bisphenol A+ICI (P<0.01) and estradiol+ICI (P<0.05) groups compared with the ICI group. Furthermore, cell numbers were increased in S and G2/M phases (P<0.05), while the apoptotic index was lower (P<0.05) and telomerase activities at 48 and 72 h were higher (P<0.05) in these groups than in the ICI group. Therefore, bisphenol A and estradiol promote HepG2 cell proliferation in vitro by inhibition of apoptosis and stimulation of telomerase activity via an estrogen receptor-dependent pathway.
Descritores: Compostos Benzidrílicos/farmacologia
Proliferação de Células/efeitos dos fármacos
Estradiol/farmacologia
Antagonistas do Receptor de Estrogênio/farmacologia
Estrogênios não Esteroides/farmacologia
/efeitos dos fármacos
HEP GTEMEFOS CELLS/efeitos dos fármacos
Fenóis/farmacologia
Telomerase/efeitos dos fármacos
-Apoptose/efeitos dos fármacos
Sobrevivência Celular/efeitos dos fármacos
Estradiol/análogos & derivados
Citometria de Fluxo
/enzimologia
HEP GTEMEFOS CELLS/enzimologia
Interfase/efeitos dos fármacos
Telomerase/metabolismo
Limites: Humanos
Responsável: BR1.1 - BIREME



página 1 de 1
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde